Home > Research projects >Projects in Clinical Studies

The Introduction of Hemay020

Hemay020, a tyrosince kinase irreversible inhibitor, is a proprietary new chemical entity being developed for treatment of Non-Small Cell Lung Cancer (NSCLC).

Lung cancer is one of the most common malignancies in the world and is the leading cause of cancer-related deaths worldwide with 1.59 million deaths accounted for yearly. Accounting for more than 80% off all cases, NSCLC is the most frequently diagnosed type of lung cancer[1,2]. About 60% of patients are diagnosed at later stages, and the 5-year survival rate is less than 20%.

Currently, methods to treat NSCLC are mainly chemotherapy and targeted theory drugs, both of which carry serious side effects such as bone marrow suppression, nerve toxicity and cardiac toxicity.

Hemay020, finding success, is currently undergoing clinical studies in China.

 

References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 2016, 66 (1): 7:30.

[2] Herbst RS, Heymach JV, Lippman SM. Lung cancer, New England Journal of Medicine, 2008,_359 (13): 1367 - 80.

[3] Zhang S, Fu XH. Research progress in early diagnosis for lung cancer. World Latest Medicine Information, 2016, 16 (17) : 67-68.

 

All rights reserved (2017), tianjin ICP for 05010040